CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||2.5 mg, 5mg and 10 mg|
|Indication||Advanced Breast Cancer|
|Funding Request||For treatment of post menopausal women with hormone receptor-positive advanced breast cancer in combination with exemestane, after progression or recurrence (failure) on NSAI therapy.|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|NOC Date||January 10, 2013|
|Manufacturer||Novartis Pharmaceuticals Canada Inc.|
|Sponsor||Novartis Pharmaceuticals Canada Inc.|
|Submission Date||September 5, 2012|
|Submission Deemed Complete||September 12, 2012|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||September 19, 2012|
|Check-point meeting||October 31, 2012|
|pERC Meeting||February 21, 2013|
|Initial Recommendation Issued||March 7, 2013|
|Feedback Deadline ‡||March 21, 2013|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued||March 25, 2013|
|Notification to Implement Issued||April 11, 2013|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.